Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 daclatasvir + peginterferon alfa-2a + ribavirin in treatment-naive chronic hepatitis C genotype 4
2011-002793-23Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Chronic Hepatitis C Genotype 4 comparing daclatasvir + peginterferon alfa-2a + ribavirin with placebo + peginterferon alfa-2a + ribavirin (2 arms). Primary endpoint: SVR12. Started Nov 2011; status: completed.
02
Drugs
daclatasvir
03
Conditions
Chronic Hepatitis C Genotype 4
Beyond the preview
Go deeper on 2011-002793-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002793-23.